

CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE CONTROVERSIES & UPDATES IN VASCULAR SURGERY



JANUARY 23-25 2014 —

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE

Slerosant agents to treat venous and lymphatic malformations: an overview of the past 10 years

A Bisdorff-Bresson, Gilles Soulez, J Dubois, JL Gérard, P E Burrows, E Houdart Lariboisière hospital & Mondor, Paris, France CHUM-University & St Justine Hospital, Montréal, Canada Texas, USA



www.cacvs.org

Disclosure

I do not have any potential conflict of interest

Sclerosing materials/agents

- Liquid agents: Foam/ETOH/Bleomycine
 A5,Doxycycline
- Semi liquid agents: glue/Onyx/Ethanol gel
- Permanent agents: Plug/Coils
- Endovenous thermal ablation / radiofrequency ablation



Agent choice depends on lesion type and location + extension : resorbable ??

VM treatment : direct puncture
















Aetoxisclerol 3% foam: 1/3 dilution





GVM

Necrosis Aetoxi 3% foam: 50-50%







II) ETOH/Lipiodol mixture

Still a very efficient sclerosant agent, although side effects






ETOH

- Requires general anesthesia
- Very/ Most efficient sclerosing agent
- Not expensive

But Possible major complications: 2d to ETOH sclero

- Venous drainage ++ : DVT /
 PE
- Transient nerve palsy
- Arterial : occlusion (exceptional)
- Death: 2 cases in France

Before





After









before




after

after


Before and After






Before and after ETOH











After 7 sclero sessions

ETOH Complication in VM ttt











Transient facial nerve palsy after left temporal ETOH sclero

III) Bleomycine = liquid sclerosant agent


Glycopeptide antibiotic produced by the bacterium streptomyces verticillus. Usually, it is used as an **antineoplastic drug** to treat many kinds of cancer, such as lymphoma, cervical cancer, head and neck cancer, and testicular cancer.

Bleomycin A5, also named **pingyangmycin**, is the most commonly used sclerosing agent for the treatment of vascular anomalies in China

Due to potential toxicity related to **pulmonary fibrosis** there is limited experience with Bleomycin for the treatment of VM/LM in North America and Europe .

Courtesy Dr G Soulez, Montréal

Severe cervicofacial VM; progression; trach dependent. TTT Bleomycine




Courtesy PE Burrows, USA





Before
Courtesy PE Burrows, USA


<u>After</u>






<u>After</u>










diffuse IMVM of the calf: 25 Y/O F, pain ++



DEEP IMVM
USE of
Non resorbable material
Can be usefull








2 d sclero
Permanent
material:
ONYX 2008:
D 30 pain = 0












Permanent material : Histoacryl cast



Truncular VM





Prior glue embo





Post glue occlusion


Milka Greiner




Mixture of ETOH + cellulose













Sclerogel=ETOH gel in between liquid /non resorbable material



Less painfull ETOH, slowly resorbable

Endovascular laser treatment

Endovascular laser treatment




Advantages :

- Possible under LA + direct puncture technique under US guidance
- Promising results on small pouches diameter < 1 cm (energy delivery : 250 J/cm in 7mm pouch; 100j/cm in a 5mm pouch ; 65J/cm in 3mm)
- can be used simultaneously with Ethanol sclerosis , coils etc

Disadvantages


Deep and large pouches remain difficult to treat, (difficulty in visualizing the catheter tip on US)



Dr JL Gérard, Paris




















Post 1 laser session at 1 year



Result after 2 laser ttt sessions under LA

B Faucon








D 10 post laser

after 4 laser ttt sessions under GA































E Sauvaget avant et après 2 séances de laser endovasculaire





Before and after endovascular laser treatment : post wall> lateral wall





Pre and post « laser excision »

Laser complications ..learning curve required





Post surgery








Treatment options in LM

- Macrocystic > Microcystic
- Surgical TTT
- Sclerotherapy liquid agents ++++
 Ethanol / doxycycline/ OK 432
 /bleomycine)
- Endovenous laser treatment












ETOH sclerotherapy




ETOH





Prior Bléomycine


Macrocystic LM




Post bleomycine

15 ml/session

Courtesy <u>Dr G Soulez</u>, <u>Montréal</u>





Prior Bléomycine

Post

Microcystic LM : 15 units of bleomycin in 15 ml of NaCl and 5ml of contrast.

Courtesy Dr G Soulez, Montréal


Interstitial laser treatment on lymphatic vesicals



Conclusion

- Sclerotherapy is an efficient treatment tool in VM and LM TTT: Agent choice depends on lesion type and location + extension : resorbable ??
- Bleomycine seems to be promising agent in VM/LM TTT —even though recurrence has been observed
- **Ethanol gel** efficiency to be confirmed / price \$\$ and quantity issue (2,4ml/vial)
- Endovenous laser treatment technique is :
 - an effective modality in small < 2cm skin and mucosal VM
 - promising technique in VM TTT: patient's pain relief ++
 - Offers TTT opportunity in challenging UE + LE VM
 - Can be associated to sclerotherapy
- Vascular anomalies center (dermatologists, interventional radiologists, anesthetists, surgeons, nurses etc..)

Thanks to our Multidisciplinary Vascular anomalies group



Ainsi que

A Aymard

M Borsik

C Degrugillier-Chopinet

C Laurian

L Drouet

M Wassef

And Patricia Burrows

Our Mentors:



JJ Merland et MC Riché



Odile Enjolras